Publications
2022
Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) Cream (CAL 0.005%/BDP 0.064% w/w) Improves Plaque Psoriasis at Week One in a Phase 3 Trial
Enhanced Skin Deposition of Betamethasone Dipropionate into the Skin of Human Volunteers from Calcipotriene/Betamethasone Dipropionate Cream Compared to Topical Suspension
PAD Technology™ : A Novel Topical Formulation and Drug Delivery System
PAD Technology™ Based CAL/BDP Cream Demonstrates Superior Human Skin Flux Properties Compared to Topical Suspension/Gel
Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) Cream Demonstrates HIGH Efficacy and Convenience in Skin of Color Patients with Plaque Psoriasis